Med. pract. Stefanie Müller
Neurologie · Dept. III
Funktionelle Evaluation des autonomen Nervensystems im Zusammenhang mit der erstmaligen Einnahme von 0,5mg Fingolimod (Gilenya®) bei Patienten mit schubförmig verlaufender Multipler Sklerose
21.08.20131.Synopsis 1.1.Hintergrund der Studie Multiple Sklerose (MS) ist eine chronische, demyelinisierende, immunvermittelte Erkrankung des zentralen Nervensystems, die durch Entzündung und Zerstörung von Axonen (Nervenzellbahnen) und Myelin (Isolierschicht...
Klinische Forschung - 21.08.2013 - 18.06.2015
Abgeschlossen
Projektleitung: Vehoff Jochen
Mitarbeiter/innen: Müller Stefanie, Hundsberger Thomas
Swiss Multiple Sclerosis Cohort-Study (SMSC-Study): A Prospective Swiss wide Investigation of Key Phases in Disease Evolution and new Treatment options
01.01.2013The key aims of the Swiss Multiple Sclerosis Cohort-Study (SMSC) are (1) To maintain a long-term cohort (>10 years) representative of the MS population currently living in Switzerland. This requires effective measures to limit drop-outs and the conti...
Klinische Forschung - 01.01.2013 - 30.11.2022
Automatisch geschlossen
Projektleitung: Müller Stefanie
Long-term, prospective, observational, multinational, parallel-cohort study monitoring safety in patients with MS newly started with fingolimod once daily or treated with another approved disease-modifying therapy - FTY720
20.05.2012Long-term, prospective, observational, multinational, parallel-cohort study monitoring safety in patients with MS newly started with fingolimod once daily or treated with another approved disease-modifying therapy Study: FTY720 - 2403
Klinische Forschung - 20.05.2012 - 31.12.2018
Automatisch geschlossen
Projektleitung: Müller Stefanie
An observational study to assess persistence, adherence, quality of life, and treatment satisfaction in patients beginning therapy with the Avonex® PEN™
01.04.2012An observational study to assess persistence, adherence, quality of life, and treatment satisfaction in patients beginning therapy with the Avonex® PEN™
Klinische Forschung - 01.04.2012 - 01.04.2013
Abgeschlossen
Projektleitung: Müller Stefanie
A 32-week, patient- and rater-blinded, randomized, multicenter, parallel-group study to evaluate disease control and safety in patients with relapsing remitting multiple sclerosis transferred from previous treatment with natalizumab to fingolimod (FTY720)
01.04.2012A 32-week, patient- and rater-blinded, randomized, multicenter, parallel-group study to evaluate disease control and safety in patients with relapsing remitting multiple sclerosis transferred from previous treatment with natalizumab to fingolimod (FT...
Klinische Forschung - 01.04.2012 - 01.12.2012
Abgebrochen
Projektleitung: Müller Stefanie
Tenere Extension: A multi-center, randomized, parallel-group, rater-blinded study comparing the effectiveness and safety of teriflunomide and interferon beta-1a in patients with relapsing multiple sclerosis
01.05.2011
Klinische Forschung - 01.05.2011 - 31.12.2013
Abgeschlossen
Projektleitung: Müller Stefanie
Mitarbeiter/innen: Vehoff Jochen, Siebel Philip
A single arm, open-label, multicenter study evaluating the long-term safety and tolerability of 0.5 mg fingolimod (FTY720) administered orally once daily in patients with relapsing forms of multiple sclerosis
01.04.2011A single arm, open-label, multicenter study evaluating the long-term safety and tolerability of 0.5 mg fingolimod (FTY720) administered orally once daily in patients with relapsing forms of multiple sclerosis Study: FTY720 - 2399
Klinische Forschung - 01.04.2011 - 28.02.2012
Abgeschlossen
Projektleitung: Müller Stefanie
Cohort Study comparing Corpus Callosum Atrophy as a marker of later development of cognitive impairment in patients with early and remitting relapsing multiple sclerosis
14.03.2011Even in early stages of multiple sclerosis (MS), cognitive dysfunction is a leading cause of disability. It can have profound social and economic consequences for patients and their families. Cognitive impairment is affecting up to 65% of MS patients...
Klinische Forschung - 14.03.2011 - 31.05.2011
Abgeschlossen
Projektleitung: Yildiz Murat
Mitarbeiter/innen: Vehoff Jochen, Müller Stefanie
Neurocognitive changes in patients with remitting relapsing multiple sclerosis treated with Natalizumab
01.01.2011Neurocognitive changes in patients with remitting relapsing multiple sclerosis treated with Natalizumab
Klinische Forschung - 01.01.2011 - 31.12.2012
Abgeschlossen
Projektleitung: Yildiz Murat, Müller Stefanie
A dose blind, multicenter, extension study to determine the safety and efficasy of 2 doses of BG00012 monotherapy with Relapsin Remitting Multiple Sclerosis
01.12.2010A dose blind, multicenter, extension study to determine the safety and efficasy of 2 doses of dimethyl fumarate (BG00012) monotherapy with Relapsin Remitting Multiple Sclerosis
Klinische Forschung - 01.12.2010 - 08.12.2020
Automatisch geschlossen
Projektleitung: Müller Stefanie
Mitarbeiter/innen: Vehoff Jochen
A 4 Month, open label, multi-center study to explore the tolerability and safety and health outcomes of FTY720 in patients with relapsong forms of multiple sclerosis
01.10.2010A 4 Month, open label, multi-center study to explore the tolerability and safety and health outcomes of FTY720 in patients with relapsong forms of multiple sclerosis Study: FTY720 - 2316
Klinische Forschung - 01.10.2010 - 31.05.2011
Abgeschlossen
Projektleitung: Müller Stefanie
Substudie zu SOLAR: Untersuchung der Wirkung einer Vitamin D-Substitution auf die T-Lymphozyten bei Patienten mit schubförmig-remittierender MS unter Beahndlung mit Rebif®, EMR 200136-532
01.07.2010Substudie zu SOLAR: Untersuchung der Wirkung einer Vitamin D-Substitution auf die T-Lymphozyten bei Patienten mit schubförmig-remittierender MS unter Beahndlung mit Rebif®, EMR 200136-532
Klinische Forschung - 01.07.2010 - 31.12.2013
Abgeschlossen
Projektleitung: Müller Stefanie
Tenere: A multi-center, randomized, parallel-group, rater-blinded study comparing the effectiveness and safety of teriflunomide and interferon beta-1a in patients with relapsing multiple sclerosis
03.05.2010Primary: To assess the effectiveness of 2 doses of teriflunomide in comparison to interferon-beta 1a, evaluated by the time to failure, with failure being defined as either relapse or permanent study treatment discontinuation for any cause whichever...
Klinische Forschung - 03.05.2010 - 30.06.2011
Abgeschlossen
Projektleitung: Putzki Norman
Mitarbeiter/innen: Yildiz Murat, Siebel Philip, Vehoff Jochen, Coco Orazio, Müller Anna, Müller Stefanie
Selective S1P1 receptor agonist in Patients with Relapsing-Remitting Multiple Sclerosis
01.11.2009Multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-finding phase IIb study to evaluate the efficacy, safety, and tolerability of three doses of an oral S1P1 receptor agonist, administered for twenty-four weks in patients...
Klinische Forschung - 01.11.2009 - 01.11.2010
Abgeschlossen
Projektleitung: Putzki Norman
Mitarbeiter/innen: Yildiz Murat, Müller Anna, Siebel Philip, Müller Stefanie
A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Dose-Comparison Study to Determine the Efficacy and Safety of dimethyl fumarate (BG00012) in Subjects with Relapsing-Remitting Multiple Sclerosis
01.10.2008Randomized, Multicenter, Double-Blind, Placebo-Controlled, Dose-Comparison Study to Determine the Efficacy and Safety of dimethyl fumarate in Subjects with Relapsing-Remitting Multiple Sclerosis primary objective: determine wether dimethyl fumarat...
Klinische Forschung - 01.10.2008 - 01.12.2010
Abgeschlossen
Projektleitung: Putzki Norman, Müller Stefanie
Mitarbeiter/innen: Müller Anna, Yildiz Murat, Siebel Philip